 Allergan Inc. raised doubts about Valeant Pharmaceuticals International Inc.'s commitment to improving its transparency, as it reiterated its opposition to a $53 billion hostile takeover bid from Valeant and activist investor William Ackman.. In an investor presentation Monday, Allergan asserted Valeant's disclosures likely will confirm the Botox maker's concerns about its business model.. Valeant...
  